Regulatory approval

Published by the Health Canada.

Health Canada approved rituximab for the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkin’s lymphoma.

This is written in the approval document as:

RITUXAN (rituximab for injection) is indicated for the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkin’s lymphoma.

Citation

Hoffmann-La Roche Limited. Rituxan (rituximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00071131.PDF. Revised June 2023. Accessed June 2025.

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) CD20 + Non-Hodgkin Lymphoma Rituximab
Sensitivity (+) CD20 + Follicular Lymphoma Rituximab